Delink drug prices from R&D costs: UN

Posted on:19 Sep 2016 09:24:12

Delink drug prices from R&D costs: UN
19 September 2016 Current Affairs GK: The United Nations High-Level Panel on Access to Medicines has called for delinking drug prices from research and development (R&D) costs. The report submitted by panel calls for human rights to be placed over intellectual property laws of pharmaceutical companies and incoherence between them should be narrowed.

All countries must freely be able to use flexibilities granted under TRIPS (Trade-Related Aspects of Intellectual Property Rights) to access affordable medicines. Countries that retaliate and threaten against generic drugs makers in different countries under the TRIPS Agreement must be forced to face significant sanctions. Public health assessments must be done with every free trade negotiation to assess the possible impact on public health and creation of public health patentability criteria. 

Governments engaged in bilateral and regional trade and investment treaties should ensure that these agreements do not include provisions that interfere with their obligations to fulfil the right to health. Research institutions and universities that receive public funding must prioritize public health objectives over financial returns in their patenting and licensing practices. Governments should increase their current levels of investments to in heath technology innovation to address unmet needs.

Gk Current Affairs April 2017

25 APRIL
NEWS
24 APRIL
NEWS
22 APRIL
NEWS
21 APRIL
NEWS

Gk Current Affairs March 2017

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS

Gk Current Affairs February 2017

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
25 FEBRUARY
NEWS
24 FEBRUARY
NEWS




Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.